Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
MucositisHematopoietic Stem Cell TransplantationChemotherapy-Induced MucositisRadiation-Induced Mucositis
Interventions
OTHER

Standard Care

Participants in this arm will receive standard care for mucosal injuries, which may include oral rinses, topical treatments, and supportive care based on the type of injury.

BIOLOGICAL

MSC Supernatant + Standard Care

"Participants in this arm will receive MSC supernatant in addition to standard care. MSC supernatant will be administered as follows:~15 mL for oral mucosal injuries (mouthwash) Topical application for skin mucosal injuries (based on body surface area) 50 mL for bladder injuries (bladder irrigation)"

Trial Locations (1)

610083

RECRUITING

Department of Hematology, The General Hospital of Western Theater Command, Chengdu

All Listed Sponsors
lead

The General Hospital of Western Theater Command

OTHER